Hikma Pharmaceuticals PLC (HIKl)

2,683.71
+15.00(+0.56%)
  • Volume:
    97,694
  • Bid/Ask:
    0.00/0.00
  • Day's Range:
    2,668.00 - 2,702.00

HIKl Overview

Prev. Close
2,674
Day's Range
2,668-2,702
Revenue
1.71B
Open
2,672
52 wk Range
2,150-2,763
EPS
1.31
Volume
97,694
Market Cap
6.23B
Dividend (Yield)
0.36
(1.38%)
Average Volume (3m)
84,297
P/E Ratio
20.49
Beta
0.21
1-Year Change
22.23%
Shares Outstanding
231,435,403
Next Earnings Date
05 Aug 2021
What is your sentiment on Hikma Pharmaceuticals?
or
Market is currently closed. Voting is open during market hours.

Hikma Pharmaceuticals News

Hikma Pharmaceuticals Analysis

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesSellNeutralBuyStrong BuyStrong Buy
Technical IndicatorsStrong SellStrong SellStrong BuyStrong BuyStrong Buy
SummaryStrong SellSellStrong BuyStrong BuyStrong Buy

Hikma Pharmaceuticals Company Profile

Hikma Pharmaceuticals Company Profile

Employees
8600

Hikma Pharmaceuticals PLC develops, manufactures, and markets a range of generic, branded, and in-licensed pharmaceutical products. The company offers its products in solid, semi-solid, liquid, and injectable final dosage forms. It operates through three segments: Injectables, Generics, and Branded. The Injectables segment develops, manufactures, and sells generic injectable products primarily for use in hospitals. The Generics segment develops, manufactures, and sells oral and other non-injectable generic products for the retail market. The Branded segment develops, manufactures, markets, and sells branded generics and in-licensed products to retail and hospital markets. The company offers its products in various therapeutic areas, including anti-infective, cardiovascular, central nervous system, diabetes, oncology, pain management, anesthetic, sedative, and respiratory. It operates in the United Kingdom, the United States, the Middle East, North Africa, Europe, and internationally. The company was founded in 1978 and is based in London, the United Kingdom.

Read More
  • Touch 27 today
    0
    • Next results will be super. Wait for it to hit £32 before end of this year
      0
      • Aim listed Dark Matter Ltd, has more potential
        1
        • This will go up & up
          1
          • Not as stated here (March 11)
            1
            • Hikma will announce their results for the year ended 31 December 2019 on 27 February 2020
              0
              • Any hint of progress on Advair will send this stock much higher still !
                0
                • Underpriced without the Advair approvals ' unfortunate about the 2019 target for Advair !!!
                  0
                  • Almost got me money back !!!
                    0
                    Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
                    Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.